Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Summary of Q&AFull year for the fiscal year ending April 202610 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Full-year earnings forecastThe sales plan for the fiscal year ending April 2027 was discussed. The amount is Not disclosed
What the company explained in this material
Key points of the Q&AKey questions raised by investors at the briefing and the company's answers
Sales progress in the United States, Europe, and Australia; the management structure; sales, selling, general and administrative expenses, and headcount plans for the fiscal year ending April 2027; foreign exchange assumptions; shareholder returns; the development pipeline; investor relations activities; the listing market; takeover defenses; and other topicsBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Fourth-quarter sales in the United States increased by approximately 30% from the third quarter. The increase was driven by higher sales-force activity at the end of the fiscal year and an increase in new account openings. The upside in other fields reflected growth in urology and obstetrics and gynecology in Australia. The amount is Not disclosed
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate
US dollars¥160.40 per US dollar
Euro¥187.36 per euro
Reference dateEnd-April 2026
Revenue planAn extension of the growth trajectory through the third quarter of the fiscal year ending April 2026. Does not include highly uncertain revenue from new products, new peptides, and other sources
New initiatives
- The US sales organization, which had been divided by region, will be reorganized into a structure in which sales representatives cover both the gastroenterology and otolaryngology fields
- Strengthen functions including supply chain management, quality control, accounting, and corporate planning
- Increase development project spending and headcount to establish additional business pillars following the gastroenterology field
- Strengthen investor relations activities, including by holding small-group meetings
- The company plans to propose the introduction of online and hybrid formats for annual general meetings of shareholders as an agenda item at the annual general meeting
- Consider developing drug delivery systems (DDS) using combinations with drugs incorporating A6K
Key KPIsA metric the company considers important as a management benchmark.
- Market penetration in the US gastroenterology field20～25
- PuraStat penetration in the US EMR market15～20
- Growth rate in the US otolaryngology field200 ％Year on year against the same period last yearYear on year
Segment results
United States: Growth was reported in the gastroenterology and otolaryngology fields. Europe: Growth in the gastroenterology, pharyngeal, and urology fields in the United Kingdom. Australia: Growth in urology and obstetrics and gynecology. The amount is Not disclosedMedium-term management plan targets
A sales plan was formulated for the fiscal year ending April 2027. Growth in the gastroenterology field is expected to drive overall growth, while steady growth is anticipated in other fields. The amount is Not disclosedMarket Size / Share
Market penetration in the US gastroenterology field of approximately 20–25%; PuraStat penetration in the US EMR market of approximately 15–20%Number of employees
End-April 2026129 people
Plan for the end of April 2027Plan for 139 people at the end of April 2027
Changes during the period and hiring plan10 additional hires planned
Acquisition of treasury shares
Under consideration, but the amount, number of shares, and period for the share repurchase are Not disclosed| Item | Details |
|---|---|
| Document type | Summary of Q&A |
| Fiscal Period Covered | Full year for the fiscal year ending April 2026 |
| Full-year earnings forecast | The sales plan for the fiscal year ending April 2027 was discussed. The amount is Not disclosed |
| Segment results | United States: Growth was reported in the gastroenterology and otolaryngology fields. Europe: Growth in the gastroenterology, pharyngeal, and urology fields in the United Kingdom. Australia: Growth in urology and obstetrics and gynecology. The amount is Not disclosed |
| Breakdown of Factors Affecting the Change | Fourth-quarter sales in the United States increased by approximately 30% from the third quarter. The increase was driven by higher sales-force activity at the end of the fiscal year and an increase in new account openings. The upside in other fields reflected growth in urology and obstetrics and gynecology in Australia. The amount is Not disclosed |
| Key KPIs | Indicator name Market penetration in the US gastroenterology field / Value 20～25 / Year on year against the same period last year Not disclosed, Indicator name PuraStat penetration in the US EMR market / Value 15～20 / Year on year against the same period last year Not disclosed, Indicator name Growth rate in the US otolaryngology field / Value 200 ％ / Year on year against the same period last year Year on year |
| Number of employees | End-April 2026 129 people / Plan for the end of April 2027 Plan for 139 people at the end of April 2027 / Changes during the period and hiring plan 10 additional hires planned |
| Assumptions Underlying the Business Outlook | Exchange rate US dollars ¥160.40 per US dollar / Euro ¥187.36 per euro / Reference date End-April 2026 / Revenue plan An extension of the growth trajectory through the third quarter of the fiscal year ending April 2026. Does not include highly uncertain revenue from new products, new peptides, and other sources |
| Medium-term management plan targets | A sales plan was formulated for the fiscal year ending April 2027. Growth in the gastroenterology field is expected to drive overall growth, while steady growth is anticipated in other fields. The amount is Not disclosed |
| Acquisition of treasury shares | Under consideration, but the amount, number of shares, and period for the share repurchase are Not disclosed |
| Market Size / Share | Market penetration in the US gastroenterology field of approximately 20–25%; PuraStat penetration in the US EMR market of approximately 15–20% |
| Key points of the Q&A | Sales progress in the United States, Europe, and Australia; the management structure; sales, selling, general and administrative expenses, and headcount plans for the fiscal year ending April 2027; foreign exchange assumptions; shareholder returns; the development pipeline; investor relations activities; the listing market; takeover defenses; and other topics |
| New initiatives | The US sales organization, which had been divided by region, will be reorganized into a structure in which sales representatives cover both the gastroenterology and otolaryngology fields, Strengthen functions including supply chain management, quality control, accounting, and corporate planning, Increase development project spending and headcount to establish additional business pillars following the gastroenterology field, Strengthen investor relations activities, including by holding small-group meetings, The company plans to propose the introduction of online and hybrid formats for annual general meetings of shareholders as an agenda item at the annual general meeting, Consider developing drug delivery systems (DDS) using combinations with drugs incorporating A6K |
Items this document does not state (18)
Net SalesOperating profitOrdinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioCapital expendituresOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company disclosed investor questions and responses to strengthen information dissemination and ensure fair disclosure.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.